Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Lipid Absorption01:24

Lipid Absorption

3.3K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.3K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.5K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.5K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

7.3K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential effects of atorvastatin on calcification in stromal and vascular cells within monolayer and 3D plaque cap models.

Biochemical and biophysical research communications·2026
Same author

Cardiovascular risk profiles in patients with primary sclerosing cholangitis.

European journal of gastroenterology & hepatology·2026
Same author

VASCULAR INTERVENTIONS IN FRAIL ELDERLY PATIENTS: A BIBLIOMETRIC ANALYSIS OF GLOBAL RESEARCH OUTPUT AND CLINICAL OUTCOMES.

Georgian medical news·2026
Same author

Blood pressure patterns during pregnancy and early postpartum in preeclampsia with severe features: predictors of chronic hypertension.

Pregnancy hypertension·2025
Same author

Underrepresentation of women in cardiovascular disease clinical Trials-What's in a Name?

International journal of cardiology. Heart & vasculature·2024
Same author

Genome-wide association studies for milk production traits in two autochthonous Aosta cattle breeds.

Animal : an international journal of animal bioscience·2024
Same journal

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same journal

Causal insights of modifiable cardiovascular risk factors for dementia risk - potential for efficient prevention and improved brain health.

Atherosclerosis·2026
Same journal

Serial OCT-based coronary physiology and plaque composition in vessels with nonobstructive coronary lesions following intensive lipid-lowering therapy: YELLOW III sub-study.

Atherosclerosis·2026
Same journal

Earliest age to detect lifetime cardiometabolic health stratification in children.

Atherosclerosis·2026
Same journal

Sympathetic neurons exacerbate atherosclerosis by modulating macrophage function via the NPY/Y1R axis.

Atherosclerosis·2026
Same journal

Optimizing lipoprotein(a) testing for immediate clinical impact in primary prevention.

Atherosclerosis·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Lomitapide affects HDL composition and function.

R Yahya1, E Favari2, L Calabresi3

  • 1Department of Internal Medicine, Division Pharmacology, Vascular and Metabolic Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.

Atherosclerosis
|May 28, 2016
PubMed
Summary
This summary is machine-generated.

Lomitapide treatment in homozygous familial hypercholesterolemia (HoFH) patients reduced LDL-C and HDL-C. Cholesterol efflux capacity (CEC) changes were variable, suggesting potential benefits despite HDL-C reduction.

Keywords:
Cholesterol efflux capacityCholesterol lowering drugsHDLHomozygous familial hypercholesterolemiaLomitapide

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

1.4K

Related Experiment Videos

Last Updated: Mar 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

1.4K

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Lomitapide effectively lowers low-density lipoprotein-cholesterol (LDL-C).
  • Lomitapide's impact on high-density lipoprotein-cholesterol (HDL-C) and its functional capacity requires further investigation.
  • Understanding these effects is crucial for optimizing treatment in homozygous familial hypercholesterolemia (HoFH).

Purpose of the Study:

  • To investigate the effect of lomitapide on HDL-C levels in HoFH patients.
  • To assess the impact of lomitapide on the cholesterol efflux capacity (CEC) of HDL.
  • To evaluate the overall clinical efficacy of lomitapide in HoFH.

Main Methods:

  • Four HoFH patients received escalating doses of lomitapide.
  • Measurements included LDL-C, HDL-C levels, and HDL-mediated cholesterol efflux capacity (CEC).
  • Specific CEC pathways (ABCA1, ABCG1, SR-BI) were analyzed.

Main Results:

  • Lomitapide significantly decreased LDL-C (–34% to –89%) and total HDL-C (–16% to –34%).
  • A shift towards more buoyant HDL particles was observed.
  • ABCA1-mediated CEC significantly decreased (–39% to –99%), while other CEC pathways showed inconsistent changes.

Conclusions:

  • Lomitapide reduces both LDL-C and HDL-C levels in HoFH patients.
  • The anti-atherogenic potential of HDL may be preserved as total CEC did not consistently decrease.
  • The combined reduction of atherogenic lipoproteins and preserved HDL function suggests a net beneficial effect of lomitapide in HoFH.